title: [Valvular heart disease associated with the treatment of Parkinson disease].
abstract: Ergot derivatives (EDs) are used in the treatment of Parkinson's disease, but recent reports indicate induction of valvular heart disease. This survey reviews the documentation and reports on the design of a blinded study of 160 Parkinson's patients treated with either EDs or non-EDs. The present recommendations regarding monitoring of patients treated with ED are also described.
authors.affiliation: Arhus Universitetshospital, Skejby Sygehus, Kardiologisk Afdeling. vibeke.guldbrand@svf.au.dk
authors.forename: Vibeke Guldbrand
authors.initials: VG
authors.lastname: Rasmussen
authors.forename: Erik
authors.initials: E
authors.lastname: Dupont
authors.forename: Karen
authors.initials: K
authors.lastname: Østergaard
authors.forename: Henrik
authors.initials: H
authors.lastname: Egeblad
mesh_terms: D000978:Antiparkinson Agents / Q000009:adverse effects*; D018491:Dopamine Agonists / Q000009:adverse effects*; D004879:Ergotamines / Q000009:adverse effects*; D006349:Heart Valve Diseases / Q000139:chemically induced*; D006801:Humans; D010300:Parkinson Disease / Q000188:drug therapy*
chemical_list: D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D004879:Ergotamines